2024
Calcium channel blockers and beta blockers in pediatric supraventricular tachycardia
Sullivan J, Pompa A, Schieber J, Arora G, Dionne A, Beach C. Calcium channel blockers and beta blockers in pediatric supraventricular tachycardia. Journal Of Cardiovascular Electrophysiology 2024, 35: 2237-2241. PMID: 39313851, DOI: 10.1111/jce.16432.Peer-Reviewed Original ResearchCalcium channel blockersBeta blockersSupraventricular tachycardiaPediatric supraventricular tachycardiaChannel blockersAssociated with more side effectsCalcium-channel blockers patientsHemodynamically significant heart diseaseSide effectsMulticenter retrospective cohort studyEctopic atrial tachycardiaSignificant heart diseaseIntolerable side effectsRetrospective cohort studySuccess rateSupraventricular tachycardia diagnosisData abstraction toolAcademic children's hospitalIndividuals aged 1Pediatric arrhythmiasBB patientsDosage adjustmentAtrial tachycardiaTreatment successCohort study
2023
Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry
Crotti L, Spazzolini C, Nyegaard M, Overgaard M, Kotta M, Dagradi F, Sala L, Aiba T, Ayers M, Baban A, Barc J, Beach C, Behr E, Bos J, Cerrone M, Covi P, Cuneo B, Denjoy I, Donner B, Elbert A, Eliasson H, Etheridge S, Fukuyama M, Girolami F, Hamilton R, Horie M, Iascone M, Jiménez-Jaimez J, Jensen H, Kannankeril P, Kaski J, Makita N, Muñoz-Esparza C, Odland H, Ohno S, Papagiannis J, Porretta A, Prandstetter C, Probst V, Robyns T, Rosenthal E, Rosés-Noguer F, Sekarski N, Singh A, Spentzou G, Stute F, Tfelt-Hansen J, Till J, Tobert K, Vinocur J, Webster G, Wilde A, Wolf C, Ackerman M, Schwartz P. Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry. European Heart Journal 2023, 44: 3357-3370. PMID: 37528649, PMCID: PMC10499544, DOI: 10.1093/eurheartj/ehad418.Peer-Reviewed Original ResearchConceptsClinical presentationPrimary neurological manifestationsCardiac structural abnormalitiesLife-threatening arrhythmia syndromesArrhythmic event rateAbsence of symptomsLife-threatening arrhythmiasSodium channel blockersCongenital heart defectsAntiadrenergic interventionsCardiac eventsHeart failureNeurological manifestationsUnderlying molecular mechanismsDefinitive recommendationsClinical severityChannel blockersObservational studySudden deathIndex caseArrhythmia syndromesHeart defectsPrevalent phenotypeStructural abnormalitiesCurrent management